New therapeutic and biomarker discovery for peripheral diabetic neuropathy

PARP inhibitor, nitrotyrosine, and tumor necrosis factor-α

Viktor R. Drel, Sergey Lupachyk, Hanna Shevalye, Igor Vareniuk, Weizheng Xu, Jie Zhang, Nicholas A. Delamere, Mohammad Shahidullah, Barbara Slusher, Irina G. Obrosova

Research output: Contribution to journalArticle

Abstract

This study evaluated poly(ADP-ribose) polymerase (PARP) inhibition as anewtherapeutic approach for peripheral diabetic neuropathy using clinically relevant animal model and endpoints, and nitrotyrosine (NT), TNF-α, and nitrite/nitrate as potential biomarkers of the disease. Control and streptozotocin-diabetic rats were maintained with or without treatment with orally active PARP inhibitor 10-(4-methyl-piperazin-1-ylmethyl)-2H-7-oxa-1,2- diaza-benzo[de]anthracen-3-one (GPI-15,427), 30 mg kg-1 d -1, for 10 wk after first 2 wk without treatment. Therapeutic efficacy was evaluated by poly(ADP-ribosyl)ated protein expression (Western blot analysis), motor and sensory nerve conduction velocities, and tibial nerve morphometry. Sciatic nerve and spinal cord NT, TNF-α, and nitrite/nitrate concentrations were measured by ELISA. NT localization in peripheral nervous system was evaluated by double-label fluorescent immunohistochemistry. A PARP inhibitor treatment counteracted diabetes-induced motor and sensory nerve conduction slowing, axonal atrophy of large myelinated fibers, and increase in sciatic nerve and spinal cord NT and TNF-α concentrations. Sciatic nerve NT and TNF-α concentrations inversely correlated with motor and sensory nerve conduction velocities and myelin thickness, whereas nitrite/nitrate concentrations were indistinguishable between control and diabetic groups. NT accumulation was identified in endothelial and Schwann cells of the peripheral nerve, neurons, astrocytes, and oligodendrocytes of the spinal cord, and neurons and glial cells of the dorsal root ganglia. The findings identify PARP as a compelling drug target for prevention and treatment of both functional and structural manifestations of peripheral diabetic neuropathy and provide rationale for detailed evaluation of NT and TNF-α as potential biomarkers of its presence, severity, and progression.

Original languageEnglish (US)
Pages (from-to)2547-2555
Number of pages9
JournalEndocrinology
Volume151
Issue number6
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Diabetic Neuropathies
Peripheral Nervous System Diseases
Tumor Necrosis Factor-alpha
Biomarkers
Neural Conduction
Sciatic Nerve
Nitrites
Nitrates
Spinal Cord
Poly(ADP-ribose) Polymerases
Therapeutics
Neurons
Tibial Nerve
Schwann Cells
Oligodendroglia
Peripheral Nervous System
Spinal Ganglia
Streptozocin
Myelin Sheath
Poly(ADP-ribose) Polymerase Inhibitors

ASJC Scopus subject areas

  • Endocrinology

Cite this

Drel, V. R., Lupachyk, S., Shevalye, H., Vareniuk, I., Xu, W., Zhang, J., ... Obrosova, I. G. (2010). New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-α. Endocrinology, 151(6), 2547-2555. https://doi.org/10.1210/en.2009-1342

New therapeutic and biomarker discovery for peripheral diabetic neuropathy : PARP inhibitor, nitrotyrosine, and tumor necrosis factor-α. / Drel, Viktor R.; Lupachyk, Sergey; Shevalye, Hanna; Vareniuk, Igor; Xu, Weizheng; Zhang, Jie; Delamere, Nicholas A.; Shahidullah, Mohammad; Slusher, Barbara; Obrosova, Irina G.

In: Endocrinology, Vol. 151, No. 6, 06.2010, p. 2547-2555.

Research output: Contribution to journalArticle

Drel, VR, Lupachyk, S, Shevalye, H, Vareniuk, I, Xu, W, Zhang, J, Delamere, NA, Shahidullah, M, Slusher, B & Obrosova, IG 2010, 'New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-α', Endocrinology, vol. 151, no. 6, pp. 2547-2555. https://doi.org/10.1210/en.2009-1342
Drel, Viktor R. ; Lupachyk, Sergey ; Shevalye, Hanna ; Vareniuk, Igor ; Xu, Weizheng ; Zhang, Jie ; Delamere, Nicholas A. ; Shahidullah, Mohammad ; Slusher, Barbara ; Obrosova, Irina G. / New therapeutic and biomarker discovery for peripheral diabetic neuropathy : PARP inhibitor, nitrotyrosine, and tumor necrosis factor-α. In: Endocrinology. 2010 ; Vol. 151, No. 6. pp. 2547-2555.
@article{b150ae07698445a695b08deea9309b06,
title = "New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-α",
abstract = "This study evaluated poly(ADP-ribose) polymerase (PARP) inhibition as anewtherapeutic approach for peripheral diabetic neuropathy using clinically relevant animal model and endpoints, and nitrotyrosine (NT), TNF-α, and nitrite/nitrate as potential biomarkers of the disease. Control and streptozotocin-diabetic rats were maintained with or without treatment with orally active PARP inhibitor 10-(4-methyl-piperazin-1-ylmethyl)-2H-7-oxa-1,2- diaza-benzo[de]anthracen-3-one (GPI-15,427), 30 mg kg-1 d -1, for 10 wk after first 2 wk without treatment. Therapeutic efficacy was evaluated by poly(ADP-ribosyl)ated protein expression (Western blot analysis), motor and sensory nerve conduction velocities, and tibial nerve morphometry. Sciatic nerve and spinal cord NT, TNF-α, and nitrite/nitrate concentrations were measured by ELISA. NT localization in peripheral nervous system was evaluated by double-label fluorescent immunohistochemistry. A PARP inhibitor treatment counteracted diabetes-induced motor and sensory nerve conduction slowing, axonal atrophy of large myelinated fibers, and increase in sciatic nerve and spinal cord NT and TNF-α concentrations. Sciatic nerve NT and TNF-α concentrations inversely correlated with motor and sensory nerve conduction velocities and myelin thickness, whereas nitrite/nitrate concentrations were indistinguishable between control and diabetic groups. NT accumulation was identified in endothelial and Schwann cells of the peripheral nerve, neurons, astrocytes, and oligodendrocytes of the spinal cord, and neurons and glial cells of the dorsal root ganglia. The findings identify PARP as a compelling drug target for prevention and treatment of both functional and structural manifestations of peripheral diabetic neuropathy and provide rationale for detailed evaluation of NT and TNF-α as potential biomarkers of its presence, severity, and progression.",
author = "Drel, {Viktor R.} and Sergey Lupachyk and Hanna Shevalye and Igor Vareniuk and Weizheng Xu and Jie Zhang and Delamere, {Nicholas A.} and Mohammad Shahidullah and Barbara Slusher and Obrosova, {Irina G.}",
year = "2010",
month = "6",
doi = "10.1210/en.2009-1342",
language = "English (US)",
volume = "151",
pages = "2547--2555",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - New therapeutic and biomarker discovery for peripheral diabetic neuropathy

T2 - PARP inhibitor, nitrotyrosine, and tumor necrosis factor-α

AU - Drel, Viktor R.

AU - Lupachyk, Sergey

AU - Shevalye, Hanna

AU - Vareniuk, Igor

AU - Xu, Weizheng

AU - Zhang, Jie

AU - Delamere, Nicholas A.

AU - Shahidullah, Mohammad

AU - Slusher, Barbara

AU - Obrosova, Irina G.

PY - 2010/6

Y1 - 2010/6

N2 - This study evaluated poly(ADP-ribose) polymerase (PARP) inhibition as anewtherapeutic approach for peripheral diabetic neuropathy using clinically relevant animal model and endpoints, and nitrotyrosine (NT), TNF-α, and nitrite/nitrate as potential biomarkers of the disease. Control and streptozotocin-diabetic rats were maintained with or without treatment with orally active PARP inhibitor 10-(4-methyl-piperazin-1-ylmethyl)-2H-7-oxa-1,2- diaza-benzo[de]anthracen-3-one (GPI-15,427), 30 mg kg-1 d -1, for 10 wk after first 2 wk without treatment. Therapeutic efficacy was evaluated by poly(ADP-ribosyl)ated protein expression (Western blot analysis), motor and sensory nerve conduction velocities, and tibial nerve morphometry. Sciatic nerve and spinal cord NT, TNF-α, and nitrite/nitrate concentrations were measured by ELISA. NT localization in peripheral nervous system was evaluated by double-label fluorescent immunohistochemistry. A PARP inhibitor treatment counteracted diabetes-induced motor and sensory nerve conduction slowing, axonal atrophy of large myelinated fibers, and increase in sciatic nerve and spinal cord NT and TNF-α concentrations. Sciatic nerve NT and TNF-α concentrations inversely correlated with motor and sensory nerve conduction velocities and myelin thickness, whereas nitrite/nitrate concentrations were indistinguishable between control and diabetic groups. NT accumulation was identified in endothelial and Schwann cells of the peripheral nerve, neurons, astrocytes, and oligodendrocytes of the spinal cord, and neurons and glial cells of the dorsal root ganglia. The findings identify PARP as a compelling drug target for prevention and treatment of both functional and structural manifestations of peripheral diabetic neuropathy and provide rationale for detailed evaluation of NT and TNF-α as potential biomarkers of its presence, severity, and progression.

AB - This study evaluated poly(ADP-ribose) polymerase (PARP) inhibition as anewtherapeutic approach for peripheral diabetic neuropathy using clinically relevant animal model and endpoints, and nitrotyrosine (NT), TNF-α, and nitrite/nitrate as potential biomarkers of the disease. Control and streptozotocin-diabetic rats were maintained with or without treatment with orally active PARP inhibitor 10-(4-methyl-piperazin-1-ylmethyl)-2H-7-oxa-1,2- diaza-benzo[de]anthracen-3-one (GPI-15,427), 30 mg kg-1 d -1, for 10 wk after first 2 wk without treatment. Therapeutic efficacy was evaluated by poly(ADP-ribosyl)ated protein expression (Western blot analysis), motor and sensory nerve conduction velocities, and tibial nerve morphometry. Sciatic nerve and spinal cord NT, TNF-α, and nitrite/nitrate concentrations were measured by ELISA. NT localization in peripheral nervous system was evaluated by double-label fluorescent immunohistochemistry. A PARP inhibitor treatment counteracted diabetes-induced motor and sensory nerve conduction slowing, axonal atrophy of large myelinated fibers, and increase in sciatic nerve and spinal cord NT and TNF-α concentrations. Sciatic nerve NT and TNF-α concentrations inversely correlated with motor and sensory nerve conduction velocities and myelin thickness, whereas nitrite/nitrate concentrations were indistinguishable between control and diabetic groups. NT accumulation was identified in endothelial and Schwann cells of the peripheral nerve, neurons, astrocytes, and oligodendrocytes of the spinal cord, and neurons and glial cells of the dorsal root ganglia. The findings identify PARP as a compelling drug target for prevention and treatment of both functional and structural manifestations of peripheral diabetic neuropathy and provide rationale for detailed evaluation of NT and TNF-α as potential biomarkers of its presence, severity, and progression.

UR - http://www.scopus.com/inward/record.url?scp=77954528687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954528687&partnerID=8YFLogxK

U2 - 10.1210/en.2009-1342

DO - 10.1210/en.2009-1342

M3 - Article

VL - 151

SP - 2547

EP - 2555

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 6

ER -